Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RT001 (Botulinum Toxin Type A Topical Gel)
RT001 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| RT001 | EXPERIMENTAL | RT001 (Botulinum Toxin Type A) Topical Gel |
| Dose A | ACTIVE_COMPARATOR | Dose A RT001 |
| Dose B | ACTIVE_COMPARATOR | Dose B RT001 |
| Dose C | PLACEBO_COMPARATOR | Dose C Placebo |
| 1 | EXPERIMENTAL | RT001 (Botulinum Toxin Type A Topical Gel) |
| 2 | PLACEBO_COMPARATOR | Vehicle Control |
| Dose D | ACTIVE_COMPARATOR | RT001 Dose D; Active Comparator |
| Dose E | PLACEBO_COMPARATOR | RT001 Dose E; Vehicle Comparator |
| Name | Type | Description |
|---|---|---|
| RT001 | DRUG | RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas |
| Placebo | OTHER | Dose C Placebo |
| Vehicle Control | OTHER | Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2 |
| RT001 (Botulinum Toxin Type A Topical Gel) | DRUG | Two sequential doses of RT001 at Baseline (Day 0) and Week 2 |
| Vehicle Comparator | OTHER | Vehicle Comparator |
Inclusion Criteria: * Written informed consent including authorization to release health information * Female or male, 18 to 65 years of age and in good general health * Willing and able to follow study instructions and likely to complete all study requirements * Moderate to severe lateral canthal ...
RT001 is being developed for the treatment of moderate to severe lateral canthal lines, commonly known as crow's feet or facial wrinkles around the eyes. It is a topical gel formulation of botulinum toxin type A applied to the skin, and it is in Phase 2 clinical development for this dermatologic indication.
RT001 is developed by Revance Therapeutics, Inc., which trades under the ticker RVNC. The company is the sponsor of the clinical program evaluating RT001 for lateral canthal lines.
RT001 is in Phase 2 clinical development. It is an investigational product and has not been approved by the FDA. Four Phase 2 trials of RT001 have been completed, and no trials are currently active.
RT001 has been studied in four completed Phase 2 trials: NCT01124565, NCT00907387, NCT00888914, and NCT00884234. These trials evaluated RT001 for moderate to severe lateral canthal lines in the United States, with total enrollment of 202 participants across the program.
The RT001 Phase 2 trials were randomized, double-blind, and placebo-controlled. They enrolled adults with moderate to severe lateral canthal lines, with minimum ages of 18 or 30 years depending on the study, and included both healthy volunteers and non-healthy volunteers across the four completed trials.
Yes. RT001 is also known as RT001 (Botulinum Toxin Type A Topical Gel). It is a topical gel formulation of botulinum toxin type A developed by Revance Therapeutics for lateral canthal lines, and searches for either name refer to the same investigational asset.